Endocrine Abstracts

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

Background: Skeletal fragility is an important clinical issue in women with early-stage breast cancer and men with non-metastatic prostate cancer under hormonal hormone deprivation therapies (HDTs). Vertebral fractures (VFs) have been reported in a remarkable number of subjects exposed to HDT especially when the diagnosis of fractures is performed by a radiological and morphometric approach. Notably, prediction of fractures in this clinical setting is a challenge and determina...

Management of skeletal fragility in women with early breast cancer (BC) under hormone-deprivation therapies (HDTs) may be a challenge and it is still unknown whether anti-osteoporotic therapies could be active in preventing fractures in pre-menopausal women exposed to HDTs. In this real-world, multicenter study, we evaluated the effectiveness of bone-active drmgs and determinants of vertebral fractures (VFs) in 306 pre-menopausal women (mean age 47.15±5.09, range: 30-54) wi...